Skye Bioscience Inc SKYE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/24/24 EDT
12.85UNCH (UNCH)
Volume
108,525
52 week range
1.44 - 19.41
Loading...
  • Open13.65
  • Day High14.10
  • Day Low12.50
  • Prev Close14.03
  • 52 Week High19.41
  • 52 Week High Date03/04/24
  • 52 Week Low1.44
  • 52 Week Low Date12/01/23

Key Stats

  • Market Cap360.608M
  • Shares Out28.06M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.73
  • YTD % Change372.43

KEY STATS

  • Open13.65
  • Day High14.10
  • Day Low12.50
  • Prev Close14.03
  • 52 Week High19.41
  • 52 Week High Date03/04/24
  • 52 Week Low1.44
  • 52 Week Low Date12/01/23
  • Market Cap360.608M
  • Shares Out28.06M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.73
  • YTD % Change372.43

RATIOS/PROFITABILITY

  • EPS (TTM)-5.69
  • P/E (TTM)-2.26
  • Fwd P/E (NTM)-20.08
  • EBITDA (TTM)-34.763M
  • ROE (TTM)-1,364.20%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-205.08%

EVENTS

  • Earnings Date05/12/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Skye Bioscience Inc

 

Profile

MORE
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical...
Punit Dhillon
Chairman of the Board, President, Chief Executive Officer
Kaitlyn Arsenault CPA
Chief Financial Officer
Address
11250 EL CAMINO REAL, SUITE 100
San Diego, CA
92130
United States